Reviva Pharma Prices $10M Offering at $1.50/Unit, Shares & Warrants to Fund R&D
RVPH is trading near its 52-week low of $1.82 (40% below the low) on elevated volume (3.7× avg).
Summary
Reviva Pharmaceuticals Holdings, Inc. has announced the pricing of its public offering, raising approximately $10 million in gross proceeds. The offering includes 6,666,667 shares (or equivalents) along with Series G and H warrants, priced at a combined $1.50 per share and accompanying warrants. This follows the company's announcement of a proposed offering yesterday and a 1-for-20 reverse stock split on March 9th to maintain Nasdaq compliance. The $10 million capital raise is highly dilutive, representing a significant portion of the company's current market capitalization, and underscores an urgent need for funding, primarily for its planned RECOVER-2 Phase 3 trial for brilaroxazine. Investors should monitor the stock's reaction to this substantial dilution and the company's progress in its clinical development pipeline.
At the time of this announcement, RVPH was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8M. The 52-week trading range was $1.82 to $23.40. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.